DEFERASIROX

Post-LOE

deferasirox

ANDAORALTABLET
Approved
Apr 2025
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

(deferasirox) is an orally active chelator that is selective for iron (as Fe). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper there are variable decreases in the serum concentration of these trace metals…

Clinical Trials (5)

NCT03387475Phase 2Completed

Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents

Started Feb 2018
39 enrolled
Myelodysplasia
NCT03372083Phase 4Completed

Safety Study of Crushed Deferasirox Film Coated Tablets in Pediatric Patients With Transfusional Hemosiderosis

Started Jan 2018
44 enrolled
Iron Overload
NCT03203850Phase 2Terminated

Study to Evaluate the Efficacy and Safety of Deferasirox Film-coated Tablet Versus Phlebotomy in Patients With Hereditary Hemochromatosis (HH)

Started Jan 2018
45 enrolled
Hereditary Hemochromatosis
NCT02993224Phase 2Completed

Open-label, Multicenter Study Assessing Preference for Deferasirox Film-coated Tablet Compared to Dispersible Tablet

Started Jul 2017
148 enrolled
Transfusion-dependent ThalassemiaNon-transfusion-dependent Thalassemia
NCT02943668Phase 2Terminated

Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome

Started Mar 2017
2 enrolled
AnemiaMyelodysplastic Syndrome